In their 2022 review, Uljanovs et al. reported that, in the main studies of parafibromin expression in parathyroid tumors, loss of parafibromin was present in 0–17.6% of PAs, in 0–54.3% of APTs, and in 20–100% of PCs [71]. The gene discussed is CDC73; the disease is tumor of parathyroid gland.